These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22292379)
21. [Study on method on post-marketing traditonal Chinese medicine safety assessment]. Kou Q; Zhao S; Feng G; Xie Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361 [TBL] [Abstract][Full Text] [Related]
22. Influence of the MedDRA hierarchy on pharmacovigilance data mining results. Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751 [TBL] [Abstract][Full Text] [Related]
23. [Research on establishment of clinical safety intensive hospital monitoring net of traditional Chinese medicine injection]. Wang LX; Xie YM; Wang ZF Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2692-4. PubMed ID: 23285910 [TBL] [Abstract][Full Text] [Related]
24. [Interpretation of adverse drug reaction reporting and monitoring and significance of traditional Chinese medicine adverse drug reaction monitoring]. Wang D; Du XX Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2686-8. PubMed ID: 23285908 [TBL] [Abstract][Full Text] [Related]
25. Veterinary pharmacovigilance in the European context. Keck G Ann Ist Super Sanita; 1992; 28(4):425-8. PubMed ID: 1303032 [TBL] [Abstract][Full Text] [Related]
26. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Olivier P; Montastruc JL Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082 [TBL] [Abstract][Full Text] [Related]
27. [Clinical orientation and thought on several problems in post-marketed reassessment of traditional Chinese medicine]. Wang X; Su X; Yu J; Xie Y; Wang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2893-7. PubMed ID: 22292394 [TBL] [Abstract][Full Text] [Related]
28. Pharmacovigilance: characteristics of the most widely used drugs in Bulgaria. Getov I; Dimitrova Z Cent Eur J Public Health; 1999 Aug; 7(3):133-6. PubMed ID: 10499144 [TBL] [Abstract][Full Text] [Related]
29. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine]. Wei X; Zhang Z; Xie Y; Wang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389 [TBL] [Abstract][Full Text] [Related]
30. [Research about re-evaluation of screening of traditonal Chinese medicine symptoms item of post-marketing medicine Xuezhikang]. He W; Xie Y; Wang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2898-900. PubMed ID: 22292395 [TBL] [Abstract][Full Text] [Related]
32. Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database. Bondon-Guitton E; Sommet A; Montastruc JL; Pharmacopsychiatry; 2009 Mar; 42(2):61-5. PubMed ID: 19308880 [TBL] [Abstract][Full Text] [Related]
33. [Studies on market of drug delivery system product and drug delivery system of compound Chinese medicine]. Feng Y; Xu DS; Hong YL; Zhang N; Ma YM Zhongguo Zhong Yao Za Zhi; 2006 Oct; 31(20):1669-70, 1688. PubMed ID: 17225529 [TBL] [Abstract][Full Text] [Related]
34. Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica. Bian ZX; Tian HY; Gao L; Shang HC; Wu TX; Li YP; Zhang BL; Song L J Evid Based Med; 2010 Feb; 3(1):5-10. PubMed ID: 21349034 [TBL] [Abstract][Full Text] [Related]
35. Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. Yuen MF; Tam S; Fung J; Wong DK; Wong BC; Lai CL Aliment Pharmacol Ther; 2006 Oct; 24(8):1179-86. PubMed ID: 17014576 [TBL] [Abstract][Full Text] [Related]
36. Spontaneous reporting of adverse drug events by Korean regional pharmacovigilance centers. Shin YS; Lee YW; Choi YH; Park B; Jee YK; Choi SK; Kim EG; Park JW; Hong CS Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):910-5. PubMed ID: 19621345 [TBL] [Abstract][Full Text] [Related]
37. [Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials]. Xie Y; Wang Y; Tian F; Wang Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2764-7. PubMed ID: 22292359 [TBL] [Abstract][Full Text] [Related]
38. [Guidance of FDA risk evaluation and mitigation strategy and enlightenment to drug risk management of post-marketing Chinese medicine]. Li Y; Xie Y Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2825-7. PubMed ID: 22292376 [TBL] [Abstract][Full Text] [Related]
39. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database. Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL; Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603 [TBL] [Abstract][Full Text] [Related]
40. A new model of pharmacovigilance? A pilot study. Zancan A; Locatelli C; Ramella F; Tatoni P; Bacis G; Vecchio S; Manzo L Biomed Pharmacother; 2009 Jul; 63(6):451-5. PubMed ID: 18790597 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]